Dyne Therapeutics Statistics
Total Valuation
DYN has a market cap or net worth of $3.00 billion. The enterprise value is $2.05 billion.
Important Dates
The next estimated earnings date is Monday, May 4, 2026, before market open.
| Earnings Date | May 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
DYN has 165.22 million shares outstanding. The number of shares has increased by 36.43% in one year.
| Current Share Class | 165.22M |
| Shares Outstanding | 165.22M |
| Shares Change (YoY) | +36.43% |
| Shares Change (QoQ) | +4.10% |
| Owned by Insiders (%) | 0.33% |
| Owned by Institutions (%) | 107.25% |
| Float | 156.38M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.06 |
| P/TBV Ratio | 3.07 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 22.25, with a Debt / Equity ratio of 0.17.
| Current Ratio | 22.25 |
| Quick Ratio | 21.94 |
| Debt / Equity | 0.17 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -75.61 |
Financial Efficiency
Return on equity (ROE) is -55.71% and return on invested capital (ROIC) is -32.60%.
| Return on Equity (ROE) | -55.71% |
| Return on Assets (ROA) | -31.16% |
| Return on Invested Capital (ROIC) | -32.60% |
| Return on Capital Employed (ROCE) | -41.20% |
| Weighted Average Cost of Capital (WACC) | 10.87% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.73M |
| Employee Count | 258 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +64.20% in the last 52 weeks. The beta is 1.29, so DYN's price volatility has been higher than the market average.
| Beta (5Y) | 1.29 |
| 52-Week Price Change | +64.20% |
| 50-Day Moving Average | 17.73 |
| 200-Day Moving Average | 16.43 |
| Relative Strength Index (RSI) | 46.20 |
| Average Volume (20 Days) | 1,792,873 |
Short Selling Information
The latest short interest is 21.70 million, so 13.14% of the outstanding shares have been sold short.
| Short Interest | 21.70M |
| Short Previous Month | 20.47M |
| Short % of Shares Out | 13.14% |
| Short % of Float | 13.88% |
| Short Ratio (days to cover) | 10.41 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -468.18M |
| Pretax Income | -446.21M |
| Net Income | -446.21M |
| EBITDA | -466.14M |
| EBIT | -468.18M |
| Earnings Per Share (EPS) | -$3.47 |
Full Income StatementBalance Sheet
The company has $1.11 billion in cash and $169.20 million in debt, giving a net cash position of $941.36 million or $5.70 per share.
| Cash & Cash Equivalents | 1.11B |
| Total Debt | 169.20M |
| Net Cash | 941.36M |
| Net Cash Per Share | $5.70 |
| Equity (Book Value) | 972.13M |
| Book Value Per Share | 5.89 |
| Working Capital | 1.08B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$403.21 million and capital expenditures -$20.71 million, giving a free cash flow of -$423.92 million.
| Operating Cash Flow | -403.21M |
| Capital Expenditures | -20.71M |
| Depreciation & Amortization | 2.05M |
| Net Borrowing | 148.26M |
| Free Cash Flow | -423.92M |
| FCF Per Share | -$2.57 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |